SCHEMBL4799616

SCHEMBL4799616

NC(=O)Nc1ccc(Cl)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.61
RAB9A P51151 6/20 0.61
ALDH1A1 P00352 4/20 0.61
KDM4E B2RXH2 2/20 0.61
NPSR1 Q6W5P4 1/20 0.57
RXFP1 Q9HBX9 1/20 0.57
EGFR P00533 1/20 0.55
TAS1R3 Q7RTX0 1/20 0.55
TAS1R1 Q7RTX1 1/20 0.55
TAS1R2 Q8TE23 1/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
HTT P42858 1/20 0.53
PDK1 Q15118 1/20 0.53
PDK2 Q15119 1/20 0.53
PDK3 Q15120 1/20 0.53
PDK4 Q16654 1/20 0.53
USP2 O75604 1/20 0.53
HPGD P15428 1/20 0.53
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30274478 1.00 NPC1 (0.61) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL5150505 0.84 MEN1 (0.67) NPC1RAB9AALDH1A1PDK1PDK2
SCHEMBL12919798 0.83 RAB9A (0.56) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL5471126 0.83 RAB9A (0.65) NPC1RAB9AALDH1A1KDM4EATM
SCHEMBL4098881 0.83 RAB9A (0.49) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL27672011 0.82 CXCR2 (0.59) NPC1RAB9AALDH1A1KDM4ECYP1A2
SCHEMBL9834106 0.82 RAB9A (0.57) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL1092441 0.82 KDM4E (0.58) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL2090284 0.82 RAB9A (0.54) NPC1RAB9AALDH1A1KDM4ENPSR1
SCHEMBL9035650 0.81 RAB9A (0.58) NPC1RAB9AALDH1A1KDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115850123-B Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2024-04-19 CN claimed
CN-115850123-A Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2023-03-28 CN claimed
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 WO claimed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP claimed
WO-2005105757-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO claimed
CN-115850123-B Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2024-04-19 CN disclosed
CN-115850123-A Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2023-03-28 CN disclosed
EP-1539766-B1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2016-12-21 EP disclosed
CN-104220058-A Serine racemase inhibitor NAT UNIV CORP UNIV TOYAMA 2014-12-17 CN disclosed
US-20080119503-A1 Androgen receptor modulators and methods of use thereof MERCK SHARP & DOHME CORP. 2008-05-22 US disclosed
US-7351698-B2 Androgen receptor modulators and methods of use thereof MERCK & CO., INC. (US) 2008-04-01 US disclosed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP disclosed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US disclosed
EP-1509505-A2 SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2005-03-02 EP disclosed
WO-2004087643-A1 DEFORMYLASE INHIBITOR, PROCESS FOR PREPARING THE SAME, AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME PROMEDITECH INC. (KR) 2004-10-14 WO disclosed
EP-1446110-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES Structural Bioinformatics Inc. (US) 2004-08-18 EP disclosed
WO-2004056830-A1 PYRROLOPYRIMIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed
CN-1481376-A HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS ���ĵ�˹ҩ��¹����޹�˾ 2004-03-10 CN disclosed
WO-2003062206-A2 SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2003-07-31 WO disclosed
WO-2003032916-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES STRUCTURAL BIOINFORMATICS INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP NPC1 4548/4885RAB9A 3814/4885ALDH1A1 961/4885
US-20080119503-A1 Androgen receptor modulators and methods of use thereof SHBG, FSHR, AR NPC1 4173/4885RAB9A 2899/4885ALDH1A1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.